- A Case of Refractory Pediatric Crohn's Disease with a Successful Treatment by Infliximab Therapy
-
Park SH, Jeen YT, Chun HR, Kim DI, Baeck CW, Kim YS, Chun HJ, Lee HS, Um SH, Choi JH, Kim CD, Ryu HS, Hyun JH
- KMID: 772847
- Korean J Gastroenterol.
- 2005 Oct;46(4):297-301.
Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of an Oral SMAD7 Antisense Drug for Active Crohn's Disease
-
Seo GS
- KMID: 2373243
- Korean J Gastroenterol.
- 2015 Jun;65(6):384-385.
- doi: 10.4166/kjg.2015.65.6.384
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Determining the Dose of Azathioprine Based on the Lower Limit of Leukocyte Count in Patients with Crohn's Disease
-
Seo GS
- KMID: 1775743
- Korean J Gastroenterol.
- 2013 Aug;62(2):83-84.
- doi: 10.4166/kjg.2013.62.2.83
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term Efficacy and Predictors of Response to Infliximab in Korean Patients with Crohn's Disease
-
Lee KM
- KMID: 1501644
- Korean J Gastroenterol.
- 2013 May;61(5):241-242.
- doi: 10.4166/kjg.2013.61.5.241
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A Rare Case of Free Bowel Perforation Associated with Infliximab Treatment for Stricturing Crohn's Disease
-
Lim CS, Moon W, Park SJ, Park MI, Kim HH, Kim JB, Choi JM, Chang HK, Lee SH
- KMID: 1707200
- Korean J Gastroenterol.
- 2013 Sep;62(3):169-173.
- doi: 10.4166/kjg.2013.62.3.169
Crohn's disease is characterized by chronic transmural inflammation of the bowel and is associated with serious complications, such as bowel strictures, abscesses, fistula formation, and perforation. As neither medical nor... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Late Onset-Acute Tubulointerstitial Nephritis with Infliximab and Mesalazine Treatment in a Patient with Crohn's Disease
-
Yoo YJ, Chung SY, Gu DH, Ko GJ, Pyo HJ, Kwon YJ, Bak YT, Won NH
- KMID: 2155329
- Korean J Gastroenterol.
- 2014 May;63(5):308-312.
- doi: 10.4166/kjg.2014.63.5.308
Infliximab is a chimeric anti-tumor necrosis factor-alpha monoclonal antibody. Infusion related reactions and infection are well known side effects of infliximab; however, renal complications have not been well recognized. We... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Squamous Cell Carcinoma of the Breast in a Patient with Crohn's Disease Taking Azathioprine
-
Park KC, Ju DU, Heo SW, Ryu JI, Cho JY, Kim EJ, Oh HK, Kim EY
- KMID: 1773074
- Korean J Gastroenterol.
- 2012 Dec;60(6):373-376.
- doi: 10.4166/kjg.2012.60.6.373
Azathioprine (AZA) treatment in transplant or autoimmune patients and subsequent appearance squamous cell carcinomas at various sites, particularly skin and cervix, has shown a close relationship. However, it remains uncertain... -
- CITED
-
- Close
- SHARE
-
- Close
- Mesalazine-induced Eosinophilic Pneumonia in a Patient with Crohn's Disease
-
Park JE, Hwangbo Y, Chang R, Chang YW, Jang JY, Kim BH, Dong SH, Kim HJ
- KMID: 1062815
- Korean J Gastroenterol.
- 2009 Feb;53(2):116-120.
Mesalazine (5-aminosalicylic acid) and sulfasalazine are widely used in the treatment of inflammatory bowel disease. The pulmonary toxicity related to sulfasalazine was well-recognized complication and it was caused by sulfapyridine... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Adalimumab in Korean Patients with Crohn's Disease
-
Sohn IW, Kim ST, Kim B, Lee HJ, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH
- KMID: 2363971
- Gut Liver.
- 2016 Mar;10(2):255-261.
- doi: 10.5009/gnl15165
BACKGROUND/AIMS: Adalimumab is effective for both remission induction and the maintenance of Crohn's disease (CD) in Western countries. We evaluated the efficacy of adalim-umab in the conventional step-up treatment approach... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Infliximab in the Treatment of Korean Patients with Crohn's Disease
-
Kim SH, Yang SK, Kim KJ, Kim EH, Yoon SM, Ye BD, Byeon JS, Myung SJ, Kim JH
- KMID: 1775965
- Korean J Gastroenterol.
- 2009 Aug;54(2):108-116.
- doi: 10.4166/kjg.2009.54.2.108
BACKGROUND/AIMS: Infliximab has been proven to be effective for refractory luminal and fistulizing Crohn's disease (CD). We performed this study to demonstrate the efficacy of infliximab in Korean CD patients.... -
- CITED
-
- Close
- SHARE
-
- Close
- How Should Azathioprine Be Dosed in Crohn's Disease? A Novel Strategy of Maximum Dose-titration Based on the Lower Limit of Leukocyte Count and Tolerability
-
Lim CS, Moon W, Park SJ, Park MI, Choi JM, Yoo JH, Kim JB, Lee JS
- KMID: 1775748
- Korean J Gastroenterol.
- 2013 Aug;62(2):111-116.
- doi: 10.4166/kjg.2013.62.2.111
BACKGROUND/AIMS: Although general guidelines have suggested weight-based dosing of azathioprine (AZA, 2.5 mg/kg/day) for Crohn's disease (CD), a substantial number of patients develop bone marrow suppression. The aim of this... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Crohn's Disease Having Normal Delivery after Infliximab Treatment during Early Pregnancy
-
Jang YW, Park YS, Kim SH, Jo YJ, Jo YK, Ahn SB, Seo YS, Hong YO
- KMID: 1775785
- Korean J Gastroenterol.
- 2013 Jan;61(1):37-41.
- doi: 10.4166/kjg.2013.61.1.37
Infliximab is a chimeric IgG1 monoclonal antibody to tumor necrosis factor (TNF)-alpha used in the treatment of steroid refractory or dependent Crohn's disease (CD). Patients with active CD are more... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Treatment with Infliximab in Crohn's Disease: the Experience of Single Center in Korea
-
Choi KD, Song HJ, Kim JS, Jung HC, Song IS
- KMID: 1767509
- Korean J Gastroenterol.
- 2005 Jul;46(1):48-55.
BACKGROUND/AIMS: Infliximab has been shown to be effective and safe for treating refractory luminal and fistulizing Crohn's disease (CD). The aim of this study was to report the efficacy and... -
- CITED
-
- Close
- SHARE
-
- Close
- Guidelines for the Management of Crohn's Disease
-
Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H, IBD Study Group of the Korean Association for the Study of the Intestinal Diseases
- KMID: 1792823
- Korean J Gastroenterol.
- 2012 Feb;59(2):141-179.
- doi: 10.4166/kjg.2012.59.2.141
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with uncertain etiopathogenesis. CD can involve any site of gastrointestinal tract from the mouth to anus and is associated with... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression of TIM-3, Human beta-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy
-
Kim MJ, Lee WY, Choe YH
- KMID: 2155645
- Gut Liver.
- 2015 May;9(3):370-380.
- doi: 10.5009/gnl13408
BACKGROUND/AIMS: This study investigated the expression of T cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3), human beta-defensin (HBD)-2, forkhead box protein 3 (FOXP3), and the frequency of CD4+ CD25+ FOXP3+... -
- CITED
-
- Close
- SHARE
-
- Close
- Cross-Regulation of Innate and Adaptive Immunity: A New Perspective for the Pathogenesis of Inflammatory Bowel Disease
-
Oh DY, Koh SJ
- KMID: 2155636
- Gut Liver.
- 2015 May;9(3):263-264.
- doi: 10.5009/gnl15123
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcome of Treatment with Infliximab in Crohn's Disease: A Single-Center Experience
-
Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW
- KMID: 1501649
- Korean J Gastroenterol.
- 2013 May;61(5):270-278.
- doi: 10.4166/kjg.2013.61.5.270
BACKGROUND/AIMS: Our aim was to assess the long-term data regarding efficacy and safety of infliximab (IFX) treatment for refractory Crohn's disease (CD) patients in our tertiary teaching hospital. METHODS: We have... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
-
Choi SY, Kang B, Lee JH, Choe YH
- KMID: 2412155
- Gut Liver.
- 2017 Jan;11(1):55-61.
- doi: 10.5009/gnl16041
BACKGROUND/AIMS: The clinical use of measuring infliximab (IFX) trough levels (TLs) and antibodies against IFX (ATIs) in patients with pediatric inflammatory bowel disease (IBD) remains unclear. We propose measuring these... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
-
Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH, IBD Study Group of the Korean Association for the Study of the Intestinal Diseases
- KMID: 2427155
- Yonsei Med J.
- 2016 Nov;57(6):1376-1385.
- doi: 10.3349/ymj.2016.57.6.1376
PURPOSE: Infliximab is currently used for the treatment of active Crohn's disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
-
Kim ES, Kim KO, Jang BI, Lee CK, Kim HJ, Lee KM, Kim YS, Eun CS, Jung SA, Yang SK, Lee J, Kim TO, Jung Y, Seo GS, Yoon SM, the IBD Study Group of the Korean Association for the Study of the Intestinal Diseases (KASID)
- KMID: 2411966
- Gut Liver.
- 2016 May;10(3):391-398.
- doi: 10.5009/gnl15126
BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD)... -
- CITED
-
- Close
- SHARE
-
- Close
